EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial

Jérôme Alexandre, Stephane Oudard, Lisa Golmard, Luca Campedel, Mourad Mseddi, Sylvain Ladoire, Ahmed Khalil, Denis Maillet, Christophe Tournigand, Blaise Pasquiers, Françoise Goirand, Joseph Berthier und 13 weitere

Clinical Pharmacokinetics · 2024

DOI: 10.1007/s40262-024-01396-x ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Jérôme Alexandre und 24 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Université Paris Cité, Institut du Cancer Paris CARPEM, AP-HP, Hôpital Cochin-Port Royal, 75014, Paris, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Cilag.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Trough abiraterone concentration (ABI Cmin) of 8.4 ng/mL has been identified as an appropriate efficacy threshold in patients treated for metastatic castration-resistant prostate cancer (mCRPC). The aim of the phase II OPTIMABI study was to evaluate the efficacy of pharmacokinetics (PK)-guided dose escalation of abiraterone acetate (AA) in underexposed patients with mCRPC with early tumour progression. METHODS: This multicentre, non-randomised study consisted of two sequential steps. In step 1, all patients started treatment with 1000 mg of AA once daily. Abiraterone Cmin was measured 22-26 h after the last dose intake each month during the first 12 weeks of treatment. In step 2, underexposed patients (Cmin 8.4 ng/mL) after doubling the dose, but none met the primary endpoint. In the post-hoc analysis of PK data, 32 patients (39%) were underexposed, and ABI Cmin was independently associated with worse progression-free survival [hazard ratio (HR) 2.50, 95% confidence interval (CI) 1.07-5.81; p = 0.03], in contrast to the ITT analysis. CONCLUSION: The ITT and per-protocol analyses showed no statistical association between ABI underexposure and an increased risk of early tumour progression in patients with mCRPC, while the Bayesian estimator showed an association. However, other strategies than dose escalation at the time of progression need to be evaluated. Treatment adherence appeared to be uniformly good in the present study. Finally, the use of a Bayesian approach to recover samples collected outside the predefined blood collection time window could benefit the conduct of clinical trials based on drug monitoring. OPTIMABI trial is registered as National Clinical Trial number NCT03458247, with the EudraCT number 2017-000560-15).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantHumansMaleAgedMiddle AgedAged, 80 and overDisease ProgressionDose-Response Relationship, DrugAndrostenesAbiraterone AcetateAntineoplastic AgentsNeoplasm Metastasis

Substanzen

abirateroneAndrostenesAbiraterone AcetateAntineoplastic Agents

Autor:innen und Institutionen

  • Medical Oncology Department, Université Paris Cité, Institut du Cancer Paris CARPEM, AP-HP, Hôpital Cochin-Port Royal, 75014, Paris, France.
  • Medical Oncology Department, Université Paris Cité, Institut du Cancer Paris CARPEM, AP-HP, Hôpital Européen George Pompidou, 75015, Paris, France.
  • Department of Genetics, Institut Curie, 75005, Paris, France.
  • Université Paris Sciences and Lettres, Paris, France.
  • Department of Medical Oncology, AP-HP, Hôpital Pitié-Salpêtrière, 75013, Paris, France.
  • Biologie du Médicament-Toxicologie, Institut du Cancer Paris CARPEM, AP-HP, Hôpital Cochin, 75014, Paris, France.

ORCID-Profile: Benoit Blanchet

Förderung

  • Cilag

Zitieren

APA

Alexandre, J., Oudard, S., Golmard, L., Campedel, L., Mseddi, M., Ladoire, S., Khalil, A., Maillet, D., Tournigand, C., Pasquiers, B., Goirand, F., Berthier, J., Guitton, J., Dariane, C., Joly, F., Xylinas, E., Golmard, J. L., Abdoul, H., Puszkiel, A., …, & Blanchet, B. (2024). Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01396-x

Vancouver

Alexandre J, Oudard S, Golmard L, Campedel L, Mseddi M, Ladoire S, et al. Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01396-x

BibTeX
@article{Alexandre2024,
  author = {Alexandre, Jérôme and Oudard, Stephane and Golmard, Lisa and Campedel, Luca and Mseddi, Mourad and Ladoire, Sylvain and Khalil, Ahmed and Maillet, Denis and Tournigand, Christophe and Pasquiers, Blaise and Goirand, Françoise and Berthier, Joseph and Guitton, Jérôme and Dariane, Charles and Joly, Florence and Xylinas, Evanguelos and Golmard, Jean Louis and Abdoul, Hendy and Puszkiel, Alicja and Decleves, Xavier and Carton, Edith and Thomas, Audrey and Vidal, Michel and Huillard, Olivier and Blanchet, Benoit},
  title = {Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial},
  journal = {Clinical Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s40262-024-01396-x}
}
Kostenlos starten →